Single Time Point Prediction as Earlier Diagnosis of Progressive Pulmonary Fibrosis

Pulmonary Fibrosis Clinical Trial

— IS-PPF  

Official title:

Imaging Signature of Progressive Pulmonary Fibrosis in Idiopathic Pulmonary Fibrosis and Non-IPF Interstitial Lung Diseases

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT06162884
• Other study ID #: IRB#23-001246
• Secondary ID: ECR2022-3630
• Status: Not yet recruiting
• Start date: December 22, 2023
• Est. completion date: December 31, 2027

Study information

• Verified date: November 2023
• Source: University of California, Los Angeles
• Contact: Grace Hyun Kim, PhD
• Phone: (310) 481-7594
• Email: GraceKim[@]mednet.ucla.edu
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

This study is a prospective observational study for subjects with idiopathic pulmonary fibrosis (IPF) or non-IPF interstitial lung diseases (ILD).

The purpose of this study is to compare whether imaging patterns from high-resolution computed tomography (HRCT) at baseline can predict worsening. Single Time point Prediction (STP) is a score derived from an artificial intelligenc/ machine learning (AI/ML) using the radiomic features from a HRCT scan that quantifies the imaging patterns of short-term predictive worsening.

Description:

Primary objective is to predict early for progression in both IPF and non-IPF ILD population using an artificial intelligence (AI)/ML algorithm of STP score. The primary interest is to validate STP score in identifying a cohort early for the candidate of anti-fibrotic treatment. The study plans to collect clinical information such as pulmonary function tests (PFT), symptom scores, 6-minute walk tests (6MWT), and radiological information from HRCT. This study does not intervene with patient's standard medical care.

This proposal is a prospective study that will enroll patients from the UCLA ILD Center. STP scores of subjects' baseline HRCT images will be grouped to one of 2 arms based on the baseline HRCT.

• Arm A: STP>=30% in whole lung

• Arm B: STP < 30% in whole lung

A subject's allocation will be determined by the baseline HRCT scan. STP score will be derived from the baseline HRCT to compare the early prediction of progression in ILD, STP of 30% threshold is expected to be close to the mean of overall population. In addition, a multi-scale guided attention (MSGA) is an imaging marker from deep learning model with two attention models to classify an IPF-likeliness using HRCT.

In IPF, progression-free survival (PFS) is defined by the reduction of 10% or more by FVC in volume or 15% or more by DLCO (DLCO) or death from any cause, whichever came first.

In non-IPF ILD, PFS is defined by two worsening outcomes out of three elements of PFT worsening, radiological worsening or symptom or disease-related death alone.

• Worsening in PFT is defined by 5% or more absolute decreases in the percent predicted FVC or 10% or more absolute decrease in the percent predicted DLCO.

• Radiological evidence of disease progression is defined by visual worsening (one or more of the following) from a radiological report or quantitative lung fibrosis (QLF) changes >=2% in whole lung

• Symptomatic worsening can be measure by the modified Medical Research Council (mMRC) Dyspnea scale or King's Brief Interstitial Lung Disease (K-BILD).

Secondary outcomes of this study are:

• To compare overall survival between the two arms of STP

• To compare the changes in 6-minute walk tests between the two arms of STP

• To compare PFS between two groups of MSGA marker positive and negative

• To compare overall survival between two groups of MSGA marker positive and negative

With a chronic ILD or IPF, lung function may be stable for a few years or continue to deteriorate slowly or rapidly develop more scar tissues over time. While it is known that age, biological sex, and lung function are factors that can impact risk of worsening lung function, there is a great need for better methods to predict which patients are at risk of worsening lung function. Having better methods to predict disease progression could allow more timely treatment with anti-fibrotic treatment to prevent the disease progression.

In both IPF and non-IPF ILD, HRCT scan is required for diagnosis. Imaging patterns derived from HRCT, called STP is designed to predict the areas in lung that may be likely to progress in the next 6 to 12 months. High STP scores are associated with poor prognosis and worsening the pulmonary function. The goal of this study is to test whether an AI-algorithm, the STP score from a single CT study, can predict disease progression in subjects with IPF and non IPF-ILD in a prospective study. This AI-algorithm was developed under NIH-sponsored study.

The purpose of prospective observational cohort study from UCLA is to test for the early sign of progressive fibrosis using baseline HRCT. This study, Imaging Signature of Progressive Pulmonary Fibrosis (IS-PPF) Research is a prospective study that will collect information regarding HRCT images, pulmonary function test, 6-minute walk, symptomatic score, and patients' clinical information to set up AI-driven imaging signature for evaluating the STP in predicting progression in IPF and non-IPF ILD.

This is an observational study; only minimally invasive procedures will be performed with study subjects (blood draws and nasal swabs). These biological samples will support future research studies. The study subject's will participation in the study for up to 3 years, the length of participation may vary. All subjects will continue to receive their usual care and treatment.

In summary, this research will create an opportunity to test and validate the imaging score and early prediction for IPF and non-IPF ILD that can impact current and future care practices.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 200
• Est. completion date: December 31, 2027
• Est. primary completion date: December 22, 2026
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

IPF Inclusion Criteria:

• Established a diagnosis (within 3 years) of IPF by enrolling center as defined by ATS/ERS/JRS/ALAT criteria

• Age over or equal to 40 years old

• No history of lung transplant

• FVC % predicted >= 45%

• DLCO % predicted >=25%

Non-IPF ILD Inclusion Criteria:

• Established a diagnosis (within 3 years) of IPF by enrolling center.

• Age over or equal to 18 years old

• Presence of chronic fibrosis ILD defined as architectural distortions with reticulation and the presence of traction bronchiectasis estimating visually >10% in whole lung.

• FVC % predicted >= 45%

• DLCO % predicted >=25%

Exclusion Criteria:

• Planned to participate an intervention trial within the next 3 months

• Currently listed for lung transplantation at the time of enrollment

• Malignancy, treated or untreated, other than skin cancer or prostate cancer within the past 5 years

• Exclusion of co-morbidities: congestive heart failure (stroke, deep vein thrombosis, pulmonary embolism, myocardial infarction), current virus-associated community acquired pneumonia, smoking-related chronic obstructive lung disease with FEV1 < 70%, history of lung cancer, history of other cancer treated within the past 4 years (excluding basal cell carcinoma of skin).

HRCT data from subjects with combined pulmonary fibrosis and emphysema (CPFE) can be collected.

Major Discontinuing Criteria in this study

• lung transplant after baseline or death

• withdraw of consent or transition to another care center

Related Conditions & MeSH terms

• Fibrosis
• Pulmonary Fibrosis

Locations

Country	Name	City	State
n/a

Sponsors (2)

Lead Sponsor	Collaborator
University of California, Los Angeles	Boehringer Ingelheim

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Nasal and Blood Biobanking	The biorepository of nasal and blood samples will be collected for future ancillary study proposal.	At baseline (or screening) and year 1 follow-up
Other	Estimate median PFS by the levels of STP ranging 20% to 50%	Progression Free Survival of IPF and non-IPF ILD will be compared in patients with a various threshold of STP 20% to 50%	From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 2 years
Primary	PFS between the two arms by STP	Progression Free Survival of IPF and non-IPF ILD will be compared in patients with STP >=30% or <30%.	From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 2 years
Secondary	OS between the two arms by STP score	Overall Survival will be compared with STP >=30% or <30%.	From Baseline to end of the study (up to 3 years)
Secondary	Changes in Distance Walked (Meters) on the 6MWT by two arms of STP score	The 6MWT measures the distance a patient is able to walk quickly on a flat, hard surface in a period of 6 minutes.	From Baseline in every 3-6-month to end of the study (up to 2 years)
Secondary	PFS between two arms by MSGA marker	Progression Free Survival will be compared in subjects with MSGA positive or negative marker.	From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 2 years
Secondary	OS between two arms by MSGA marker	Overall Survival of IPF and non-IPF ILD will be compared in patients with MSGA positive or negative marker.	From Baseline to end of the study (up to 3 years)